LE TRAITEMENT DE RELAIS DE LA TUBERCULOSE PULMONAIRE PAR ADMINISTRATION INTERMITTENTE DE RIFAMPICINE ET D'ETHAMBUTOL

In the present state of antituberculous chemotherapy, the intermittent administration of rifampicin and ethambutol, after a short period of daily administration, may be applicable to patients in whom the first line regime proved inefficient. Conditions should, however, be respected, particularly in developing countries. The use of these drugs should be strictly limited to specialised units able to understand the indications, to supervise the administration of the drug and to ensure close supervision of the patients. The cost of such a treatment should not be prohibitive and should not exceed the cost of a standard second line chemotherapy using classical reserve drugs.